Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.

Authors

Douglas Adkins

Washington University School of Medicine, St. Louis, MO

Douglas Adkins , Peter John Oppelt , Jessica C. Ley , Praveen Chowdary Myneni , Venkata Ramana Gogula , Satish Kanumuri , Sheshubabu Yadla , Venkata Sadu , Raghava Kota , Saipavan Sanagala , Mounika Surapaneni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.

First Author: Majd Issa

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.

First Author: A. Dimitrios Dimitrios Colevas

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.

First Author: Jared Cohen

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.

First Author: Christine H. Chung